这是用户在 2025-6-3 20:41 为 https://teams.igem.org/5918/safety/safety-preliminary-form/8e3a23a0-eb3e-464f-90f1-001182e37ec0 保存的双语快照页面，由 沉浸式翻译 提供双语支持。了解如何保存？
iGEM Competition 2025
Edit  编辑

HZAU-China  HZAU-中国

Team Page  团队页面Deliverables DashboardSafety Forms  安全表格
Preliminary Safety Form

Preliminary Safety Form  初步安全表

Deliverable Status  交付物状态
Draft  草案
Deadline  限期
June 4, 2025 23:00 (+08)
六月4,2025 23：00 （+08）

The purpose of this form is for everyone, including iGEM, to know you are doing your project safely and securely. This is how we know that everyone in iGEM is assessing and managing any risks to iGEM teams, their colleagues, participants in their research, their broader communities, or the environment. If you don't tell us how you are handling these risks, we don't know. Being transparent about possible risks and how we are managing them is a key component of being a responsible scientist or engineer, so please answer the questions as fully as possible!
此表格的目的是让每个人（包括 iGEM）知道您正在安全可靠地进行项目。这就是我们为什么知道 iGEM 中的每个人都在评估和管理对 iGEM 团队、他们的同事、他们的研究参与者、他们更广泛的社区或环境的任何风险。如果您不告诉我们您是如何处理这些风险的，我们就不知道。对可能的风险以及我们如何管理这些风险保持透明是成为负责任的科学家或工程师的关键组成部分，因此请尽可能完整地回答问题！

Team  团队

2025

HZAU-China  HZAU-中国

Team ID  团队 ID
5918
Kind  类
Collegiate  高校
Primary PI  主要 PI
Binguang Ma  马宾光

Contact Info  联系信息

Who from your team should be contacted about this form?
应就此表单联系您团队中的谁？
Wentao Yang (@yangwent)  杨文涛 （@yangwent）

1. Following iGEM's rules and policies
1. 遵守 iGEM 的规则和政策

Prohibited activities  禁止的活动

Using organisms from Risk Group 3 or 4
使用风险组 3 或 4 中的生物体
Using parts from an organism in Risk Group 4
使用来自风险组 4 中生物体的部分
Releasing or deploying a genetically modified organism outside the lab
在实验室外释放或部署转基因生物
Testing your product on humans (including yourselves)
在人类（包括您自己）上测试您的产品
1. Are you planning to do any of the activities listed above?
1. 您打算进行上述任何活动吗？
2. Please read over iGEM’s White List ↗. Will your team use any organisms or parts not on the whitelist, or do any activities not on the whitelist?
2. 请仔细阅读 iGEM 的白名单 ↗。您的团队会使用白名单外的生物或部分，还是做白名单外的活动？

Activities that require advance permission from iGEM
需要事先获得 iGEM 许可的活动

According to iGEM’s safety policies ↗, certain kinds of work require your team to obtain advance permission from iGEM. Please submit a Check In Form ↗ (and, if applicable, an Animal Use Form ↗) to gain permission before starting work.
根据 iGEM 的安全政策 ↗，某些类型的工作需要您的团队事先获得 iGEM 的许可。请在开始工作之前提交一份签到表 ↗（以及一份动物使用表 ↗，如果适用）以获得许可。

Working with animals or samples from animals (in iGEM, “animals” are vertebrates, like rats or fish, and higher-order invertebrates, like octopus and bees) (Animal use policy ↗)
使用动物或动物样本（在 iGEM 中，“动物”是脊椎动物，如大鼠或鱼类，以及高等无脊椎动物，如章鱼和蜜蜂）（ 动物使用政策 ↗）
Bringing a product of a genetically modified organism outside the lab (Release beyond containment policy ↗)
将转基因生物的产品带出实验室（ 超出限制范围的释放政策 ↗）
Conducting laboratory experiments using human samples, such as blood, DNA, other bodily specimens, and health or psychological outcomes (Human experimentation policy ↗)
使用人体样本（如血液、DNA、其他身体样本）以及健康或心理结果进行实验室实验（ 人体实验政策 ↗）
Using parts or organisms obtained from anywhere other than a trusted commercial or institutional supplier (Environmental samples policy ↗)
使用从受信任的商业或机构供应商以外的任何地方获得的部件或生物体（ 环境样本政策 ↗）
Biasing the inheritance frequency of a genetic marker in an organism’s progeny, i.e. creating a gene drive (Gene drives policy ↗)
使生物体后代中遗传标记的遗传频率产生偏差，即创建基因驱动（ 基因驱动政策 ↗）
Increasing risks from antimicrobial resistance, such as by using novel resistance factors (Antimicrobial resistance policy ↗)
增加抗微生物药物耐药性的风险，例如使用新型耐药性因子（ 抗微生物药物耐药性政策 ↗）
3. Are you planning to do any of the activities mentioned above that require advance permission from iGEM?
3. 您是否打算进行上述任何需要事先获得 iGEM 许可的活动？
4. Are you collecting any data about people, such as their opinions, quotations, medical history, gender, behavior, attitudes, or concerns?
4. 您是否收集有关人们的任何数据，例如他们的观点、引述、病史、性别、行为、态度或担忧？
For good reasons, many countries require formal approval for Human Subjects Research, as well as consent procedures for participants. You may need formal permission from a Research Ethics Committee, Institutional Research Board, or equivalent. Remember compliance with relevant laws and regulations is a requirement for participation in iGEM.
有充分的理由，许多国家/地区要求正式批准人类受试者研究，以及参与者的同意程序。您可能需要获得研究伦理委员会、机构研究委员会或同等机构的正式许可。请记住，遵守相关法律法规是参与 iGEM 的必要条件。

2. About your lab  2. 关于您的技工所

5. Does your project involve lab work and your team has plans to access lab space?
5. 您的项目是否涉及实验室工作，并且您的团队有计划使用实验室空间？
Please upload a photo or two of your lab showing the relevant safety features. Available file formats: .png, .jpg, .webp
请上传一两张您的实验室照片，展示相关的安全功能。可用文件格式： .png、.jpg、.webp
1748762666553-1.webp

1748762666553-1.webp

View  视图
1748762671108-2.webp

1748762671108-2.webp

View  视图
1748762674753-3.webp

1748762674753-3.webp

View  视图
1748762676973-4.webp

1748762676973-4.webp

View  视图
1748762678810-5.webp

1748762678810-5.webp

View  视图
What is the biosafety level of your work space?
您的工作空间的生物安全水平如何？
If you are working in a biosafety cabinet it may be a biosafety level 2 space (then select Level 2), but biosafety cabinets are sometimes also used in a biosafety level 1 laboratory to provide a sterile work space (then select Level 1). If in any doubt, please discuss this with a biosafety professional or your instructors, supervisors or lab techs to make sure you understand how the equipment you use helps to manage risks. See also the guidance on risk groups ↗.
如果您在生物安全柜中工作，则可能是生物安全 2 级空间（然后选择 2 级），但生物安全柜有时也用于生物安全 1 级实验室，以提供无菌工作空间（然后选择 1 级）。如有任何疑问，请与生物安全专业人员或您的讲师、主管或实验室技术人员讨论，以确保您了解您使用的设备如何帮助管理风险。另请参阅 risk groups ↗ 指南 。
Which work areas will you use / are you using to handle biological materials?
您将使用/正在使用哪些工作区域来处理生物材料？
Please check all the containment provisions you are using
请检查您正在使用的所有密封规定

3. About your project  3. 关于您的项目

6. Describe the goal of your project: what is your engineered organism (or other synthetic biology product, system, or tool) supposed to do?
6. 描述您的项目目标：您的工程生物体（或其他合成生物学产品、系统或工具）应该做什么？
Even though your project might change, please describe the main project idea you are working on right now, including specific technical details. See the example answers for help.
即使您的项目可能会发生变化，请描述您现在正在处理的主要项目想法，包括具体的技术细节。请参阅示例答案以获取帮助。

Our engineered bacteria exert their effects by delivering three important functional modules via extracellular vesicles (OMVs). First, they target and degrade HIF-1α proteins, inhibiting their induction of angiogenesis in hypoxic environments and reducing the expansion of the haemorrhoidal venous plexus. Second, they utilise anti-VEGF antibodies to block the VEGF pathway, further inhibiting the expansion of the haemorrhoidal venous plexus. Third, they secrete engineered bee venom peptides, which exert potent anti-inflammatory effects, alleviating local oedema and pain. Additionally, OMVs bind with wound homing peptides, guiding them to specifically aggregate at the haemorrhoidal wound site. Furthermore, the engineered bacteria possess a ‘suicide’ mechanism, whereby their activity is inhibited when patients cease consuming black rice, thereby reducing off-target risks.
我们的工程细菌通过细胞外囊泡 （OMV） 传递三个重要的功能模块来发挥作用。首先，它们靶向并降解 HIF-1α 蛋白，抑制它们在低氧环境中诱导血管生成并减少痔静脉丛的扩张。其次，它们利用抗 VEGF 抗体阻断 VEGF 通路，进一步抑制痔静脉丛的扩张。第三，它们分泌工程蜂毒肽，发挥强大的抗炎作用，缓解局部水肿和疼痛。此外，OMV 与伤口归巢肽结合，引导它们在痔疮伤口部位特异性聚集。此外，工程细菌具有“自杀”机制，当患者停止食用黑米时，它们的活性会受到抑制，从而降低脱靶风险。

Bad example answers: (not enough detail)
错误示例答案 ：（不够详细）

  • We are engineering E. coli to cure liver cancer.
    我们正在设计大肠杆菌来治疗肝癌。
  • Climate change is a very important problem. Our algae will reduce CO2 emissions and fight climate change.
    气候变化是一个非常重要的问题。我们的藻类将减少二氧化碳排放并应对气候变化。

Good example answers:
很好的示例答案 ：

  • Our bacteria will be engineered to interact with human cells. They will detect tumor cells that express biomarkers for liver cancer. They will use invasin to enter the tumor cells, and then secrete apoptin to kill the tumor cells.
    我们的细菌将被设计为与人体细胞相互作用。他们将检测表达肝癌生物标志物的肿瘤细胞。它们会利用侵袭蛋白进入肿瘤细胞，然后分泌细胞凋亡素来杀死肿瘤细胞。
  • Our algae will receive gases high in CO2. We will increase their expression of Photosystem II proteins to make them absorb more CO2 from the gas.
    我们的藻类将接收 CO2 含量高的气体。我们将增加它们对 Photosystem II 蛋白的表达，使它们从气体中吸收更多的 CO2。

7. Will you be engineering whole organisms, including viruses and cell lines in your project?
7. 您是否会在项目中对整个生物体进行工程改造，包括病毒和细胞系？
Which whole organisms, including viruses and cell lines, will you engineer in your project?
您将在项目中设计哪些完整的生物体，包括病毒和细胞系？
Check all that apply.These would be the organism(s) in which you are planning to put your parts or which you are modifying in your project.
勾选所有适用项。 这些是您计划将零件放入其中或在项目中修改的有机体。
Please list strains  请列出菌株

Escherichia coli DH5-alpha, Escherichia coli BL21, Saccharomyces cerevisiae AH109, Escherichia coli Nissle 1917
大肠埃希菌 DH5-α， 大肠埃希菌 BL21， 酿酒酵母 AH109， 大肠杆菌 Nissle 1917

8. Will you use any other organisms in your project? List organisms, including genus, species, and strain.
8. 您会在您的项目中使用任何其他生物吗？列出生物体，包括属、种和菌株。
For example, without engineering an organism directly, you might plan to extract RNA or DNA from the organism, or test your product on it.
例如，如果不直接对生物体进行工程改造，您可能计划从生物体中提取 RNA 或 DNA，或在其上测试您的产品。

mammalian HUVEC (SV40) and HEK293 cell lines
哺乳动物 HUVEC （SV40） 和 HEK293 细胞系

9. As part of your project, are you planning to make / have made new parts or substantively changed existing parts in the Registry?
9. 作为您项目的一部分，您是否计划制作/已经制作新部件或对注册表中的现有部件进行实质性更改？
10. Could any of your parts be hazardous on their own and/or in the context of your project?
10. 您的任何部件本身和/或在您的项目环境中是否有害？
11. What synthesis screening is done for the DNA/RNA that your team will use?
11. 您的团队将使用的 DNA/RNA 进行哪些合成筛选？
One set of standards for synthesis screening is maintained by the International Gene Synthesis Consortium ↗.
一套用于合成筛选的标准由国际基因合成联盟 ↗ 维护。
12. What experiments will you do with your organisms and parts?
12. 您将对您的生物体和器官进行哪些实验？
Please explain briefly. We are particularly keen to understand the boundaries or scope of your project. You should include the names of species / cell lines / strains. You should include experiments involving parts taken from other organisms, even if they are being synthesized rather than isolated from nature – you need not include any parts already in the registry.
请简单解释一下。我们特别热衷于了解您项目的边界或范围。您应该包括物种/细胞系/菌株的名称。您应该包括涉及从其他生物体中提取的部分的实验，即使它们是合成的而不是从自然界中分离的——您不需要包括注册表中已有的任何部分。

We need to verify the protein expression of Escherichia coli, so we will use Escherichia coli BL21(DE3) for protein expression and purification.
我们需要验证大肠杆菌的蛋白表达，因此我们将使用大肠杆菌 BL21（DE3） 进行蛋白表达和纯化。

Our parts sequence was synthesised by a commercial supplier and will be converted to Escherichia coli DH5α to construct an expression vector. To this end, we will conduct plasmid extraction and transformation experiments.
我们的部分序列由商业供应商合成，并将转换为大肠杆菌 DH5α 以构建表达载体。为此，我们将进行质粒提取和转化实验。

We will express anti-VEGF antibodies and conduct ELISA experiments to verify their effectiveness.
我们将表达抗 VEGF 抗体并进行 ELISA 实验以验证其有效性。

To verify the binding of artificially designed proteins to HIF-1α and their ubiquitination activity, we will use E. coli to express and purify the corresponding proteins and conduct quantitative ubiquitination experiments in vitro, which will be analysed by Western blot.
为了验证人工设计的蛋白质与 HIF-1α 的结合及其泛素化活性，我们将使用大肠杆菌表达和纯化相应的蛋白质，并在体外进行定量泛素化实验，这将通过 Western blot 进行分析。

We will use fluorescence confocal microscopy and membrane potential measurements to characterise engineered OMVs.
我们将使用荧光共聚焦显微镜和膜电位测量来表征工程 OMV。

We will use fluorescence intensity to verify the effectiveness of the riboswitch and quorum sensing systems. 重试    错误原因

We will validate the physiological functions of anti-VEGF antibodies and CAR proteins using mammalian HUVEC (SV40) and HEK293 cell lines from commercial suppliers. 重试    错误原因

Example answers  示例答案
  • Our bacteria is meant to live on plant leaves, so we will test them on tobacco (Nicotiana benthamiana) in a lab greenhouse.
    我们的细菌本来就应该生活在植物的叶子上，所以我们将在实验室温室的烟草 （Nicotiana benthamiana） 上测试它们。
  • We want to use a protein from ants, but its sequence is unknown. So we will capture ants (Camponotus spp.) to extract DNA and RNA to find the sequence of the protein we want.
    我们想使用一种来自蚂蚁的蛋白质，但它的序列未知。因此，我们将捕获蚂蚁 （Camponotus spp.） 来提取 DNA 和 RNA，以找到我们想要的蛋白质序列。
  • Our bacteria need to interact with human cells for a medical application. We will test them in human cell culture using the HEK293 cell line.
    我们的细菌需要与人体细胞相互作用才能用于医疗应用。我们将使用 HEK293 细胞系在人类细胞培养物中测试它们。
  • We are interested in a RNA-binding protein expressed in Kluyveromyces lactis. We have found the sequence in a paper and will have it synthesized by a commercial provider.
    我们对乳酸克鲁维酵母中表达的 RNA 结合蛋白感兴趣。我们已经在一篇论文中找到了这个序列，并将由商业提供商进行合成。
  • Our project will not involve experiments with organisms or parts. We will run digital directed evolution experiments to identify a candidate receptor binding protein for our fungicide.
    我们的项目不会涉及生物体或部分的实验。我们将进行数字定向进化实验，以确定我们的杀菌剂的候选受体结合蛋白。
13. Are you using some kind of hazardous chemicals in your project?
13. 您是否在项目中使用了某种危险化学品？
Microbiology labs often use many types of chemical reagents. For example, ethanol used to clean lab benches is highly flammable. Your team should have access to the safety data sheets for these reagents to understand the chemical hazards in your lab.
微生物学实验室经常使用多种类型的化学试剂。例如，用于清洁实验室工作台的乙醇是高度易燃的。您的团队应该能够访问这些试剂的安全数据表，以了解您实验室中的化学危害。
14. Is your team using or planning to use an Artificial Intelligence (AI) tool(s) for the development of your project?
14. 您的团队是否正在使用或计划使用人工智能 （AI） 工具来开发您的项目？
Which category of AI tool(s) are you using or planning to use for your project?
您正在或计划在项目中使用哪一类 AI 工具？
Check all that apply  勾选所有适用项
What risks, if any, do you foresee arising from the use of these AI tools in your project? What measures will you take to identify and mitigate these risks?
您预计在您的项目中使用这些 AI 工具会产生哪些风险（如果有）？您将采取哪些措施来识别和减轻这些风险？

No risks foreseen.  未预见到任何风险。

4. Identifying project risks
4. 识别项目风险

15. Are there any hazards presented by the organisms, parts, chemicals, or experiments you described in Part 3?
15. 您在第 3 部分中描述的生物体、部件、化学品或实验是否存在任何危害？
Please comment  请评论

5. Anticipating future risks
5. 预测未来风险

16. Imagine that, in the future, your project was fully developed into a real product that real people could use. How would people use it?
16. 想象一下，在未来，您的项目被完全开发成真实的人可以使用的真实产品。人们将如何使用它？
Check all that apply.Note: we understand that a real world use of your project might require doing experiments that would not be allowed during the competition, like releasing modified organisms into the environment.
勾选所有适用项。 注意：我们理解，在实际使用您的项目时，可能需要进行比赛期间不允许的实验，例如将改性生物体释放到环境中。
Please describe how your project would be used in the real world.
请描述您的项目在现实世界中将如何使用。

Our engineered bacteria can be taken orally and work with black rice to slow down and treat haemorrhoids. We've also designed an external medication for inflammation that can be applied topically.
我们的工程细菌可以口服，并与黑米一起作用，以减缓和治疗痔疮。我们还设计了一种可以局部使用的炎症外用药物。

17. If you were permitted, would the continued development of your project require release beyond containment?
17. 如果您被允许，您的项目的持续开发是否需要在收容后发布？
A definition of release beyond containment may be found in the relevant safety policy ↗.
有关超出收容范围的释放的定义，请参阅相关的安全政策 ↗ 。
Briefly (1-3 sentences), describe what experiments, tests, or final uses would need to take place outside of laboratory containment. Include any institutional approval processes or national regulations that you are aware you would need to comply with.
简要（1-3 句话）描述哪些实验、测试或最终用途需要在实验室隔离之外进行。包括您知道需要遵守的任何机构审批流程或国家/地区法规。

We aren't going to conduct experiments outside of laboratory. If rigorous safety and efficacy validation experiments demonstrate that our engineered bacteria have good safety and therapeutic effects, we will strictly adhere to the following regulations when conducting clinical trials: the Drug Administration Law, the Drug Registration Administration Measures, the Good Laboratory Practice (GLP) for Non-Clinical Studies of Drugs, the Good Clinical Practice (GCP) for Drug Clinical Trials, the Ethical Review Measures for Biomedical Research Involving Human Subjects, the Biosafety Law, the Regulations on the Administration of Human Genetic Resources, the Regulations on the Administration of Laboratory Animals, and the Regulations on the Registration and Information Disclosure Management of Drug Clinical Trials. Additionally, in preliminary experiments, we will strictly adhere to the ‘Law of the People's Republic of China on Biosafety,’ the ‘Regulations on the Management of Laboratory Animals,’ and the ‘Good Laboratory Practice (GLP)’ for experiments. Of course, in this project, we do not intend to conduct experiments outside the laboratory.
我们不会在实验室之外进行实验。如果严格的安全性和有效性验证实验表明我们的工程菌具有良好的安全性和治疗效果，我们在进行临床试验时将严格遵守以下规定：《药品管理法》、《药品注册管理办法》、《药物非临床研究良好实验室规范》（GLP）、《药物临床试验良好临床规范》（GCP）、 《涉及人体生物医学研究伦理审查办法》《生物安全法》《人类遗传资源管理条例》《实验动物管理条例》《药物临床试验注册与信息公开管理条例》。此外，在初步实验中，我们将严格遵守《中华人民共和国生物安全法》、《实验动物管理条例》和《良好实验室规范 （GLP）》进行实验。当然，在这个项目中，我们并不打算在实验室之外进行实验。

Bad outcomes  不良结果

The possibility of a bad outcome does not mean your project is bad; virtually all modern biotechnology presents some risk. Being a responsible synthetic biologist requires you to think about how to manage risks to ensure your project has a positive impact as it enters the real world.
坏结果的可能性并不意味着你的项目很糟糕;几乎所有现代生物技术都存在一些风险。成为一名负责任的合成生物学家需要您考虑如何管理风险，以确保您的项目在进入现实世界时产生积极影响。

Below are some illustrative examples of harm that a project could cause:
以下是项目可能造成的伤害的一些说明性示例：

Harm to human health and safety
对人类健康和安全的危害
Harm to agricultural animals, crops, or domesticated animals
对农业动物、农作物或家养动物的伤害
Harm to materials, equipment, and infrastructure
对材料、设备和基础设施的危害
Harm to the environment, including wild plants and animals
对环境的危害，包括野生动植物
Reducing global, national or health security
降低全球、国家或卫生安全
Creating or reinforcing of social inequities
制造或强化社会不平等
Breaking norms about engineering biology
打破工程生物学的规范
18. Have people on your team had a conversation (within your team or with someone outside the team) about how any of the bad outcomes above might relate to your project?
18. 你团队中的人是否（在你的团队内部或与团队外的人）就上述任何不良结果可能与你的项目有什么关系进行过对话？
Check all that apply  勾选所有适用项
19. Considering the future use(s) and conversations from the previous questions, do you think your project could potentially lead to any of the bad outcomes listed above?
19. 考虑到前面问题的未来用途和对话，您认为您的项目是否可能导致上述任何不良结果？
20. If your project were fully developed, could any of your engineered organisms or parts spread autonomously in the environment?
20. 如果您的项目已完全开发，您的任何工程生物或部件是否可以在环境中自主传播？
Organisms or parts might enter the environment intentionally (e.g. in field trials) or accidentally.
生物体或部件可能是有意（例如在田间试验中）或意外进入环境的。
Describe these strategies and why you chose them
描述这些策略以及您选择它们的原因

We introduced a riboswitch that inhibits bacterial suicide into the engineered bacteria. When no ligand molecules are present, suicide is initiated to ensure that the engineered bacteria can self-destruct when necessary, thereby ensuring biosafety.
我们引入了一种核糖开关，可抑制细菌自杀进入工程细菌。当不存在配体分子时，开始自杀以确保工程细菌在必要时能够自毁，从而确保生物安全。

6. Managing risks  6. 管理风险

21. Who are the experts, other than your supervisor(s), supporting you in managing risks? If you discover a hazard or risk in your project, who would you go to for help?
21. 除了您的主管之外，谁是支持您管理风险的专家？如果您在项目中发现危险或风险，您会向谁寻求帮助？
You might plan to seek help from institutional biosafety officers or others that have expertise with the experimental techniques, organisms, or parts involved in your project.Please provide contact information if available.
您可能打算向机构生物安全官员或对您的项目所涉及的实验技术、生物体或部件具有专业知识的其他人寻求帮助。 请提供联系信息（如有）。

Professor Qi Yingchun, Professor Wu Shanyu and Professor Xia Chunjiao from the Experimental Teaching Center of the College of Life Science and Technology, Huazhong Agricultural University, support us in managing risks.And when risks arise in our project, we will first seek help from these three teachers.
华中农业大学生命科学与技术学院实验教学中心的齐迎春教授、吴善玉教授和夏春娇教授支持我们管理风险。而当我们的项目出现风险时，我们会首先寻求这三位老师的帮助。

22. What safety and security rules or guidance cover your work?
22. 您的工作涵盖哪些安全和安保规则或指南？
In your country / region, what are the laws and regulations that govern biosafety or biosecurity in research laboratories? At your institution, what are the guidelines for laboratory biosafety and biosecurity? Please provide a link to these resources, or briefly describe them if you cannot find a link.
在您所在的国家/地区，管理研究实验室生物安全或生物安保的法律和法规有哪些？您所在机构的实验室生物安全和生物安保指南是什么？请提供这些资源的链接，如果找不到链接，请简要描述它们。

1.General requirements for laboratory biosafety GB19489 -2008
1.实验室生物安全通用要求 GB19489 -2008

2.Biosecurity Law of the People's Republic of China (https://www.mee.gov.cn/ywgz/fgbz/fl/202303/t20230314_1019536.shtml)
2.中华人民共和国生物安全法 （https://www.mee.gov.cn/ywgz/fgbz/fl/202303/t20230314_1019536.shtml）

3.Safety management measures for Huazhong Agricultural University Laboratories(https://jab.hzau.edu.cn/info/1017/1651.htm)
3.华中农业大学实验室安全管理措施（https://jab.hzau.edu.cn/info/1017/1651.htm）

23. Will your project need extra support or review to manage the risks you have identified above?
23. 您的项目是否需要额外的支持或审查来管理您上面确定的风险？
By “extra”, we mean support or review beyond what happens for every life sciences project at your institution.
我们所说的“额外”是指超出您所在机构每个生命科学项目的支持或审查。
24. Have your team members received any safety and/or security training?
24. 您的团队成员是否接受过任何安全和/或安保培训？
For the purposes of iGEM, safety and security training covers the procedures and practices used to manage risks from accidents or deliberate misuse of your projects.
就 iGEM 而言，安全和安保培训涵盖用于管理事故或故意滥用项目风险的程序和实践。
Please select the topics that you learned about (or will learn about) in your safety and security training.
请选择您在安全和安保培训中学到（或将要学习）的主题。
25. What laboratory biosafety and biosecurity measures are you using to manage the risks in your project?
25. 您使用哪些实验室生物安全和生物安全措施来管理项目中的风险？
This could include actions your team decided on or actions required by your advisors or institution. Select as many as are relevant.
这可能包括您的团队决定的行动或您的顾问或机构要求的行动。选择尽可能多的相关内容。
26. What other actions have you taken to manage the risks in your project?
26. 您还采取了哪些其他措施来管理项目中的风险？
This could include voluntary actions or actions required by your advisors or institution.
这可能包括自愿行动或您的顾问或机构要求的行动。
Please briefly describe how the risk management actions you checked above apply to your project.
请简要描述您上面检查的风险管理措施如何应用于您的项目。

Every member of our laboratory has passed the safety training before starting experiments, including biosafety, fire safety, electrical safety, and so on.
我们实验室的每一位成员在开始实验前都通过了安全培训，包括生物安全、消防安全、电气安全等。

We filled in and submitted the check in form with some parts or organisms that may have safety issues.
我们填写并提交了检查表，其中包含一些可能存在安全问题的部件或生物体。

We discussed the safety-related issues in our project with Professor Qi, Proffesor Wu and Professor Xia.
我们与齐教授、吴教授和夏教授讨论了项目中与安全相关的问题。

We introduced a riboswitch that inhibits bacterial suicide into the engineered bacteria. When no ligand molecules are present, suicide is initiated to ensure that the engineered bacteria can self-destruct when necessary, thereby ensuring biosafety.
我们引入了一种核糖开关，可抑制细菌自杀进入工程细菌。当不存在配体分子时，开始自杀以确保工程细菌在必要时能够自毁，从而确保生物安全。

Until the therapeutic effects and safety of the engineered bacteria have been fully justified on a credible experimental basis, we have decided not to carry out animal experiments.
在可信的实验基础上充分证明工程细菌的治疗效果和安全性之前，我们决定不进行动物实验。

We discussed the safety of OMV transport proteins with Dr. He Jin from the School of Life Science and Technology, Huazhong Agricultural University, and exchanged information on the safety of medicinal food collaboration for the treatment of haemorrhoids with Mr Wei Xuetuan from the School of Food Science and Technology, Huazhong Agricultural University.
我们与华中农业大学生命科学与技术学院的何进博士讨论了 OMV 转运蛋白的安全性，并与华中农业大学食品科学与技术学院的魏学团先生就药食合作治疗痔疮的安全性进行了交流。

27. Overall, how will the actions you’ve taken, expert support, rules, training, and other procedures and practices you described help you to manage the risks in your project?
27. 总的来说，您采取的行动、专家支持、规则、培训以及您描述的其他程序和做法将如何帮助您管理项目中的风险？
Please provide a detailed answer. You might include more information on:
请提供详细的答案。您可以提供以下方面的更多信息：
  • The rules and guidance you identified
    您确定的规则和指南
  • The training you have had
    您接受过的培训
  • The equipment and spaces you had or will have access to
    您曾经或将要访问的设备和空间
  • Waste treatment / inactivation procedures
    废物处理 / 灭活程序
  • Other procedures and protocols you will follow
    您将遵循的其他程序和协议

Our lab locates in the main hall of College of Life Science and Technology, Huazhong Agricultural University. The main hall is equipped with an access control system, which can identify the student’s ID and only allow authorized students to enter. The teacher in charge of safety management at our college provides safety training for each team member and routinely inspects our lab for safety compliance. Professor Qi Yingchun is responsible for the safety and security of the experimental building. She worked as a security guard at Huazhong Agricultural University for decades, and taught biological experiments in the university. Every year, before the iGEM project officially starts the experiment, each team member must attend the safety education meeting held by Professor Qi and Professor Xia and pass the corresponding online laboratory safety examination. Our laboratory is equipped with the fume hood, medicine cabinet. In addition, all the biological waste generated during the experiments is managed by trained stuff. So all of this measures can ensure that we can do experiment in a safe environment. In addition to adhering to iGEM's safety policies and rules, all experiments in our laboratory will be conducted in accordance with the "Laboratory Safety Management Measures of the College of Life Science and Technology" (No. 3, 2023), issued by the college. Meanwhile, in handling emergencies, we will follow the "Emergency Response Plan for Unexpected Safety Accidents in the First Comprehensive Building" and the "Fire Emergency Response Plan for the First Comprehensive Building".
我们的实验室位于华中农业大学生命科学与技术学院的主厅。主厅设有门禁系统，可以识别学生证，只允许获得授权的学生进入。本院负责安全管理的老师为每位团队成员提供安全培训，并定期检查实验室的安全合规性。齐迎春教授负责实验楼的安全保障。她在华中农业大学当了几十年的保安，并在大学里教授生物实验。每年，在 iGEM 项目正式启动实验之前，每个团队成员都必须参加由齐教授和夏教授举办的安全教育会议，并通过相应的在线实验室安全考试。我们的实验室配备了通风柜、药柜。此外，实验期间产生的所有生物废物都由训练有素的人员管理。所以所有这些措施都可以确保我们可以在安全的环境中进行实验。除了遵守 iGEM 的安全政策和规则外，我们实验室的所有实验都将按照学院发布的《生命科学与技术学院实验室安全管理办法》（2023 年第 3 号）进行。同时，在处理突发事件时，我们将遵循《第一综合建筑意外安全事故应急预案》和《第一综合建筑消防应急预案》。

28. Is there anything else you would like us to know?
28. 您还有什么想让我们知道的吗？
This might be about risks associated with your project, how you are managing them, or your compliance with iGEM’s safety and security rules and policies; above improvements you would like to see to our safety and security efforts; about anything that has not been sufficiently clear, or where additional guidance would be useful; and anything else you think would be relevant.
这可能涉及与您的项目相关的风险、您如何管理这些风险，或者您对 iGEM 安全和安保规则和政策的遵守情况;您希望看到我们的安全和安保工作的上述改进;关于任何不够明确的内容，或额外指导有用的内容;以及您认为相关的任何其他内容。

No  不